Literature DB >> 6486953

Tracheoesophageal fistula from carcinoma of the esophagus.

P N Symbas, P P McKeown, C R Hatcher, S E Vlasis.   

Abstract

The records of the patients with tracheoesophageal fistula from carcinoma of the esophagus treated from 1970 to 1983 were reviewed to assess the length and quality of their survival. Twenty-four patients with malignant tracheoesophageal fistula were treated during this period. The site of the carcinoma was the middle third of the esophagus in 18 patients, the lower third in 5, and the upper third in 1. Three patients received only supportive treatment, and 1 had only radiation therapy. Nine patients underwent insertion of a Mousseau-Barbin or Celestin tube with or without gastrostomy, and 7 patients had gastrostomy alone. Four patients had exclusion of the tracheoesophageal fistula, 3 with esophagogastrostomy and 1 with colon interposition. The 3 patients who received only supportive treatment survived 5 days, 1 week, and 2 weeks. The 7 patients who had gastrostomy lived 3 days to 18 weeks (mean, 6 weeks). The 9 patients with a Mousseau-Barbin or Celestin tube lived 1 week to 6 months (mean, 8 weeks). The 4 patients who had exclusion of the tracheoesophageal fistula survived 5 weeks, 4 months, 7 months, and 26 months following operation. This study suggests that the treatment for patients with tracheoesophageal fistula from carcinoma of the esophagus should be individualized and that in selected patients, exclusion of the fistula with esophagogastrostomy improves the quality of life and prolongs survival.

Entities:  

Mesh:

Year:  1984        PMID: 6486953     DOI: 10.1016/s0003-4975(10)62291-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA).

Authors:  Moon Ki Choi; Yeon Hee Park; Jung Yong Hong; Hee Chul Park; Yong Chan Ahn; Kwanmien Kim; Yong-Mok Shim; Won Ki Kang; Keunchil Park; Young-Hyuck Im
Journal:  Med Oncol       Date:  2009-11-19       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.